期刊
CANCER CELL
卷 23, 期 1, 页码 23-34出版社
CELL PRESS
DOI: 10.1016/j.ccr.2012.11.017
关键词
-
资金
- Virginia and D.K. Ludwig Fund
- SPARK at Stanford University
- National Institutes of Health [SPORE P50-CA058184]
- Flight Attendant Medical Research Institute
- Burroughs Wellcome Fund
Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据